Monitoring of Oral Cancer Patients Using Novel Lab-on-a-Chip Ensembles

使用新型芯片实验室整体监测口腔癌患者

• 批准号: 7854787
• 负责人: JOHN T MCDEVITT
• 金额: $ 101.23万
• 依托单位: RICE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-25 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7854787
• 关键词: Algorithms; Award; Biological Markers; Biological Neural Networks; Biopsy; Biopsy Specimen; Cancer Patient; Categories; Cells; Classification; Clinic; Clinical; Computer software; Data; Dentists; Detection; Development; Diagnosis; Diagnostic Procedure; Dysplasia; Elements; Erythroplasia; Health; Health Care Costs; Health Sciences; Hour; Human; Image Analysis; Institution; Keratosis; Lesion; Leukoplakia; Lichen Planus; Logistic Regressions; Malignant - descriptor; Malignant Neoplasms; Measurement; Mechanics; Medical Device; Methodology; Methods; Microfluidics; Modeling; Molecular; Molecular Profiling; Monitor; Mucous Membrane; Myocardial Infarction; Operative Surgical Procedures; Optics; Oral Medicine; Oral Pathology; Oral cavity; Pathology; Patient Monitoring; Patients; Pattern Recognition; Process; Public Health; Receiver Operating Characteristics; Recruitment Activity; Resources; Rice; Risk; Salivary; Sampling; Science; Sensitivity and Specificity; Staging; Statistical Methods; Structure; Survival Rate; Suspension substance; Suspensions; System; Techniques; Technology; Testing; Texas; Time; Training; Translational Research; Translations; Universities; Validation; Visit; advanced disease; anticancer research; base; cancer diagnosis; case control; clinical Diagnosis; clinical application; design; innovation; malignant mouth neoplasm; member; micro-total analysis system; microchip; minimally invasive; model development; molecular marker; mortality; mouth squamous cell carcinoma; nano; novel; novel diagnostics; novel strategies; outcome forecast; point of care; programs; public health relevance; sample collection; scalpel; sensor; standard of care; statistics; tumor progression

DESCRIPTION (provided by applicant): Oral cancer, largely oral squamous cell carcinoma (OSCC), is a global health problem afflicting close to 300,000 people each year. Despite significant advances in surgical procedures and treatment, the long-term prognosis for patients with OSCC remains poor, with a 5-year survival rate at approximately 50% which is among the lowest for all major cancers. High mortality associated with OSCC is often attributed to the advanced disease stage of many OSCCs upon initial identification and surgical biopsy, underscoring the need for new diagnostic methods targeting early tumor progression and malignant transformations. We propose here a broad, innovative, high impact and cross-cutting translational research program that targets development, testing and validation of powerful new microchip sensor systems for the diagnosis, prognosis and monitoring of potentially malignant lesions (PML) and malignant lesions of the oral cavity. This effort pairs the leading group involved in development of nano-bio-chip systems with leading clinicians in pathology and oral cancer research. To support the testing and validation of the new microchip sensor systems, subjects will be recruited that are diagnosed clinically with a suspicious, potentially malignant (provisional clinical diagnosis of leukoplakia or erythroplakia) or oral squamous cell carcinoma, where a conventional biopsy is indicated. The programmable nano-bio-chip (PNBC) to be developed through this program will allow for the analysis of cellular samples obtained from a minimally invasive brush biopsy sample. The cell suspensions collected in this manner will allow for the simultaneous quantification of cell morphometric data and expression of molecular biomarkers of malignant potential in an automated manner using refined image analysis algorithms based on pattern recognition techniques and advanced statistical methods. This novel PNBC approach, which will turn around biopsy results in a matter of minutes as compared to days for traditional pathology methods, has already demonstrated its ability to distinguish between normal mucosa and oral cancer lesions. We propose here to adapt this chip-based platform to include a panel of biomarkers indicative of dysplasia as derived from cytomorphometric and molecular data as well as to assess the capabilities of this approach to function in point of care settings using noninvasive brush biopsy samples. The PNBC approach will be compared to the current standard of care based on biopsy and histopathological assessment of the lesions. The multi-institution, multi-disciplinary team assembled with members from Rice University, the Universities of Texas Health Science Centers in Houston and San Antonio, and the University of Sheffield, offers unique patient based case/control resources, biomarker and pathology proficiency combined with the expertise in integrated microchip sensors that will allow the team to develop new diagnostic aids for oral cancer patients that are desperately needed. PUBLIC HEALTH RELEVANCE: Despite significant advances in surgical procedures and treatment, the long-term prognosis for patients with oral cancer remains among the lowest for all major cancers. In contrast, if detected early, the prognosis for oral cancer patients is excellent with more than 90% five-year survival. We propose the development of a minimally-invasive brush biopsy test for oral cancer diagnosis (no scalpel biopsy would be required) that when combined with a novel microchip can be performed in clinics or dentist's offices with results that are available in a matter of minutes (within visit) versus hours for scalpel biopsies. This "pathology on a chip method" could facilitate regular monitoring of patients at risk of developing oral cancer as well as those receiving treatment. The new methods are projected to benefit greatly both patients and clinicians, while at the same time lowering associated healthcare costs.

描述(申请人提供)：口腔癌，主要是口腔鳞状细胞癌(OSCC)，是一个全球性的健康问题，每年困扰着近30万人。尽管在外科手术和治疗方面取得了重大进展，但口腔鳞癌患者的长期预后仍然很差，5年生存率约为50%，是所有主要癌症中最低的之一。与口腔鳞状细胞癌相关的高死亡率通常归因于许多口腔鳞状细胞癌在最初鉴定和手术活检时处于晚期，这突显了针对早期肿瘤进展和恶变的新诊断方法的必要性。我们在这里提出了一个广泛的、创新的、高影响的和交叉的转换研究计划，旨在开发、测试和验证强大的新型微芯片传感器系统，用于诊断、预测和监测潜在的恶性病变(PML)和口腔恶性病变。这项工作将参与纳米生物芯片系统开发的领导小组与病理学和口腔癌症研究方面的领先临床医生配对。为了支持新的微芯片传感器系统的测试和验证，将招募临床诊断为可疑的、潜在的恶性(白斑或红斑的临时临床诊断)或口腔鳞状细胞癌的受试者，这些患者需要进行传统的活组织检查。通过该计划开发的可编程纳米生物芯片(PNBC)将允许对从微创刷检样本获得的细胞样本进行分析。以这种方式收集的细胞悬液将允许使用基于模式识别技术和先进统计方法的改进图像分析算法，以自动方式同时量化细胞形态测量数据和恶性潜在分子生物标志物的表达。这种新的PNBC方法，与传统的病理学方法相比，它将在几分钟内扭转活检结果，已经证明了其区分正常粘膜和口腔癌病变的能力。我们建议调整这个基于芯片的平台，以包括一组生物标记物，指示细胞形态和分子数据衍生的异型增生，并使用非侵入性刷检样本评估这种方法在护理点环境中发挥作用的能力。PNBC方法将与目前基于病变活检和组织病理学评估的护理标准进行比较。这个多机构、多学科的团队由来自莱斯大学、德克萨斯大学休斯顿和圣安东尼奥健康科学中心以及谢菲尔德大学的成员组成，提供独特的基于患者的病例/对照资源、生物标记物和病理熟练程度，以及集成微芯片传感器的专业知识，使团队能够为迫切需要的口腔癌症患者开发新的诊断辅助工具。 公共卫生相关性：尽管在外科手术和治疗方面取得了重大进展，但口腔癌患者的长期预后仍然是所有主要癌症中最低的。相比之下，如果及早发现，口腔癌患者的预后很好，五年存活率超过90%。我们建议开发一种用于口腔癌诊断的微创刷检(不需要手术刀活检)，当与新型微芯片相结合时，可以在诊所或牙医办公室进行，结果只需几分钟(在访问范围内)即可获得，而手术刀活检只需数小时。这种“芯片上的病理方法”可以促进对口腔癌高危患者和接受治疗的患者的定期监测。预计新方法将极大地惠及患者和临床医生，同时降低相关的医疗成本。